Brent C. Schneider

Brent C. Schneider is an accomplished marketing professional with extensive experience in the pharmaceutical industry, currently serving as Senior Director of US Marketing at Madrigal Pharmaceuticals since November 2021. Schneider played a pivotal role in launching Rezdiffra (resmetirom), the first FDA-approved treatment for NASH with moderate to advanced liver fibrosis, and excels in strategic brand building and promotional execution. Previous roles include Associate Director at Clovis Oncology, where Schneider led the launch of Rubraca, and various marketing positions at The Janssen Pharmaceutical Companies, contributing to significant growth for products including STELARA® and REMICADE®. Schneider's early career includes strategic consulting at Elevar and research roles at ContraFect Corp and The George Washington University. Brent C. Schneider holds an MBA in Healthcare from The Johns Hopkins University and an MSPH in Microbiology/Infectious Diseases from The George Washington University.